Diabetes patients taking Avandia or Actos are two times as likely to develop heard problems, according to a report published in the August issue of Diabetes Care.
An advisory panel hearing Monday will examine whether Avandia’s cardiovascular risks warrant a stronger warning label following a U.S. government review found Avandia’s heart risks are far higher than Actos’..
Avandia (rosiglitazone) and Actos (pioglitazone) are from the same family of diabetes drugs and used by more than 3 million diabetic patients across the United States.
For more information on this subject, please refer to our section on Drugs, Medical Devices, and Implants.
